Kidney, Diabetes and Metabolism

Abstract

Over the past five years, understanding metabolism related to managing type 2 diabetes mellitus and nephropathy has reached a level not seen in decades. The introduction of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and selective nonsteroidal mineralocorticoid receptor antagonists (Finerenone) offers physicians new tools for nephroprotection programs. We present the posters from the conference.